FABIO GRUNSPUN PITTA

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 31
  • conferenceObject
    Two-year Follow-up Of Patients With Chronic Ischemic Heart Disease In A Specialized Center In Brazil
    (2021) PINESI, Henrique Trombini; MOREIRA, Eduardo M.; BOLTA, Paula M.; MARTINS, Eduardo B.; PITTA, Fabio G.; REZENDE, Paulo C.; LIMA, Eduardo G.; HUEB, Whady; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • bookPart
    Aterosclerose Coronária
    (2016) PITTA, Fabio Grunspun; LIMA, Eduardo Gomes; RAMIRES, José Antonio Franchini; SERRANO JR., Carlos V.
  • bookPart
    Drogas endovenosas utilizadas em pacientes com insuficiência cardiaca
    (2018) MATOS, Juliano Sabino de; SOUZA, Germano Emílio Conceição; BARRETTO, Antônio Carlos Pereira; PITTA, Fabio Grunspun
  • bookPart
    Doença renal crônica e doença arterial coronariana
    (2022) PITTA, Fabio Grunspun Pitta
  • conferenceObject
    CHARACTERIZATION, TREATMENT AND OUTCOMES OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE IN A TERTIARY-CARE CENTER IN BRAZIL
    (2020) MOREIRA, Eduardo; GARZILLO, Cibele; AYRES, Sandra; FAVARATO, Desiderio; PITTA, Fabio; LIMA, Eduardo Gomes; HUEB, Whady; SERRANO, Carlos
  • conferenceObject
    Gender-related Differences in the Management of Chronic Coronary Syndrome: Registry Data of a Tertiary Center in Brazil
    (2020) SERRANO, Carlos V.; MOREIRA, Eduardo M.; GARZILLO, Cibele L.; MONTENEGRO, Luiz M.; TABUSE, Cindy L.; KORMANN-MOREIRA, Mylena C.; SEGRE, Alexandre W.; BOLTA, Paula M.; FAVARATO, Desiderio; PITTA, Fabio G.; LIMA, Eduardo G.; REZENDE, Paulo H.; HUEB, Whady A.
  • bookPart
    Novas terapias em perspectiva na aterosclerose
    (2022) FEITOSA, Mateus Paiva Marques; PITTA, Fabio Grunspun; GAZ, Marcus Vinícius Burato; LIMA, Eduardo Gomes
  • article 1 Citação(ões) na Scopus
    Evaluation of cardiovascular risk biomarkers after moderate consumption of red wine and cacha?a in a randomized crossover trial: The Wine and Cacha?a Study (WICAS)
    (2022) CELLIA, Pedro Henrique de Moraes; LIMA, Eduardo Gomes; ANGELI, Luiz Renato Agrizzi de; MARTINS, Eduardo Bello; RACHED, Fabiana Hanna; PITTA, Fabio Gruspun; STRUNZ, Celia Maria Cassaro; JR, Carlos Vicente Serrano
    Introduction: Moderate daily consumption of alcohol (MDCA) is associated with cardiovascular risk (CVR) reduction in observational studies. Some researches have suggested that this benefit may be associated not only with red wine consumption but also with other beverages. However, there are no clinical trials evaluating the possible CVR benefit of Brazilian spirit (cachaca) in humans. Methods: This is a prospective, randomized, crossover study including healthy individuals initially assigned to a MDCA of cachaca or red wine for a period of 4 weeks. After a one-week abstinence period, the type of drink was changed for another 4 weeks of intervention. The MDCA for both beverages was determined as a dose equivalent to 28 g of ethanol per day for men and 14 g for women. CVR biomarkers analyses were performed before and after each intervention to assess the serologic status of C-reactive protein, lipid profile, platelet aggregation and glycemic profile. This study is registered on the ISRCTN platform under number 15978506. Results: Of the 42 subjects initially randomized, 2 refused to continue in the study. The median age was 44.3 +/- 10.3 years and 19 were male (47.5%). Adherence to the protocol was considered ideal with 100% regular use in both interventions and only 3 individuals in each intervention group reported alcohol abuse. There was no significant variation in anthropometric measurements during the study, except for weight gain (0.7 kg) in the red wine group (p = 0.005). The median of the delta of platelet aggregation for MDCA of cachaca was 1.2% (-1.1 to 5.3) and the median of the delta to the MDCA of wine was -1.6% (-4.5 to 2) (p = 0.02). The other biomarkers didn't show any statistically significant variation. Conclusion: Moderate consumption of wine and cachaca was related to variation in laboratory biomarkers of CVR related to atherosclerosis. There was significant weight gain during the period of wine consumption and there was observed a difference between platelet aggregation values after both interventions.
  • conferenceObject
    Neither Moderate Consumption of Sugarcane Liquor (""Cachaca"") Nor of Red Wine Affect Cardiovascular Risk Biomarkers in Healthy Individuals
    (2020) CELLIA, Pedro H.; LIMA, Eduardo G.; MOREIRA, Eduardo; BARBOSA, Livia B.; PITTA, Fabio G.; RACHED, Fabiana H.; STRUNZ, Celia M.; FAVARATO, Desiderio; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • article 0 Citação(ões) na Scopus
    Coronavirus disease-2019 and heart: assessment of troponin and cardiovascular comorbidities as prognostic markers in patients hospitalized with coronavirus disease-2019 in a tertiary center in Brazil
    (2023) PINESI, Henrique Trombini; GIUGNI, Fernando Rabioglio; MATUCK, Bruna Romanelli Scarpa; PITTA, Fabio Grusnpun; GARZILLO, Cibele Larrosa; LIMA, Eduardo Gomes; KALIL FILHO, Roberto; SERRANO JUNIOR, Carlos Vicente
    OBJECTIVE: Our study aimed to evaluate the correlation of cardiac troponin T levels with comorbidities and in-hospital outcomes in patients with coronavirus disease-2019 in Brazil.METHODS: Data from a cohort of 3,596 patients who were admitted with suspected coronavirus disease-2019 in a Brazilian tertiary center, between March and August 2020, were reviewed. A total of 2,441 (68%) patients had cardiac troponin T determined in the first 72 h of admission and were stratified into two groups: elevated cardiac troponin T (cardiac troponin T >0.014 ng/mL) and normal cardiac troponin T. Associations between troponin, comorbidities, biomarkers, and outcomes were assessed. Regression models were built to assess the association of several variables with in-hospital mortality.RESULTS: A total of 2,441 patients were embraced, of which 924 (38%) had normal cardiac troponin T and 1,517 (62%) had elevated cardiac troponin T. Patients with elevated cardiac troponin T were older and had more comorbidities, such as cardiovascular disease, hypertension, diabetes, arrhythmia, renal dysfunction, liver disease, stroke, cancer, and dementia. Patients with abnormal cardiac troponin T also had more altered laboratory parameters on admission (i.e., leukocytes, C-reactive protein, D-dimer, and B-type natriuretic peptide), as well as more need for intensive care unit, vasoactive drugs, mechanical ventilation, dialysis, and blood transfusion. All-cause mortality was markedly higher among patients with increased cardiac troponin T (42 vs. 16%, P<0.001). Multiple regression analysis demonstrated that in-hospital mortality was not independently associated with troponin elevation.CONCLUSION: This study showed that cardiac troponin T elevation at admission was common and associated with several comorbidities, biomarkers, and clinical outcomes in patients hospitalized with coronavirus disease-2019, but it was not an independent marker of in-hospital mortality.